File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1006/clin.1996.0006
- Scopus: eid_2-s2.0-0029921228
- PMID: 8599882
- WOS: WOS:A1996TW58100006
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: A prospective study on anti-endothelial cell antibodies in patients with systemic lupus erythematosus
Title | A prospective study on anti-endothelial cell antibodies in patients with systemic lupus erythematosus |
---|---|
Authors | |
Issue Date | 1996 |
Citation | Clinical Immunology And Immunopathology, 1996, v. 78 n. 1, p. 41-46 How to Cite? |
Abstract | IgG anti-endothelial cell antibodies (AECA) were detected in 48.5% of patients with active systemic lupus erythematosus (SLE) and in 7% of patients during remission and were associated with the development of diffuse proliferative lupus nephritis. Sixteen AECA-positive patients were prospectively studied for 25.2 ± 2.9 months. Serial AECA levels correlated with disease activity in 10 (62.5%) patients. Seven (43.8%) of 16 patients remained AECA positive during clinical remission, Among four episodes of disease exacerbation and 16 instances of clinical improvement, 85% (17 episodes) were accompanied by corresponding changes in the level of AECA, while corresponding changes in C3, anti-nuclear antibodies, and anti-double-stranded DNA antibodies were noted in 60, 60, and 80% of cases, respectively (p = not significant). AECA served as the only serologic marker of altered disease activity in five episodes, when C3, ANA, and anti-double-stranded DNA levels remained unaltered. We conclude that the level of AECA can serve as a marker of disease activity in SLE and that serial monitoring of AECA can complement other serologic parameters in the management of patients. |
Persistent Identifier | http://hdl.handle.net/10722/162144 |
ISSN | |
ISI Accession Number ID | |
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chan, TM | en_US |
dc.contributor.author | Cheng, IKP | en_US |
dc.date.accessioned | 2012-09-05T05:17:36Z | - |
dc.date.available | 2012-09-05T05:17:36Z | - |
dc.date.issued | 1996 | en_US |
dc.identifier.citation | Clinical Immunology And Immunopathology, 1996, v. 78 n. 1, p. 41-46 | en_US |
dc.identifier.issn | 0090-1229 | en_US |
dc.identifier.uri | http://hdl.handle.net/10722/162144 | - |
dc.description.abstract | IgG anti-endothelial cell antibodies (AECA) were detected in 48.5% of patients with active systemic lupus erythematosus (SLE) and in 7% of patients during remission and were associated with the development of diffuse proliferative lupus nephritis. Sixteen AECA-positive patients were prospectively studied for 25.2 ± 2.9 months. Serial AECA levels correlated with disease activity in 10 (62.5%) patients. Seven (43.8%) of 16 patients remained AECA positive during clinical remission, Among four episodes of disease exacerbation and 16 instances of clinical improvement, 85% (17 episodes) were accompanied by corresponding changes in the level of AECA, while corresponding changes in C3, anti-nuclear antibodies, and anti-double-stranded DNA antibodies were noted in 60, 60, and 80% of cases, respectively (p = not significant). AECA served as the only serologic marker of altered disease activity in five episodes, when C3, ANA, and anti-double-stranded DNA levels remained unaltered. We conclude that the level of AECA can serve as a marker of disease activity in SLE and that serial monitoring of AECA can complement other serologic parameters in the management of patients. | en_US |
dc.language | eng | en_US |
dc.relation.ispartof | Clinical Immunology and Immunopathology | en_US |
dc.subject.mesh | Adult | en_US |
dc.subject.mesh | Antibodies, Antinuclear - Biosynthesis - Blood | en_US |
dc.subject.mesh | Autoantibodies - Biosynthesis - Blood | en_US |
dc.subject.mesh | Cells, Cultured | en_US |
dc.subject.mesh | Endothelium, Vascular - Immunology | en_US |
dc.subject.mesh | Female | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Lupus Erythematosus, Systemic - Blood - Epidemiology - Immunology | en_US |
dc.subject.mesh | Male | en_US |
dc.subject.mesh | Prospective Studies | en_US |
dc.subject.mesh | Severity Of Illness Index | en_US |
dc.title | A prospective study on anti-endothelial cell antibodies in patients with systemic lupus erythematosus | en_US |
dc.type | Article | en_US |
dc.identifier.email | Chan, TM:dtmchan@hku.hk | en_US |
dc.identifier.authority | Chan, TM=rp00394 | en_US |
dc.description.nature | link_to_subscribed_fulltext | en_US |
dc.identifier.doi | 10.1006/clin.1996.0006 | en_US |
dc.identifier.pmid | 8599882 | - |
dc.identifier.scopus | eid_2-s2.0-0029921228 | en_US |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-0029921228&selection=ref&src=s&origin=recordpage | en_US |
dc.identifier.volume | 78 | en_US |
dc.identifier.issue | 1 | en_US |
dc.identifier.spage | 41 | en_US |
dc.identifier.epage | 46 | en_US |
dc.identifier.isi | WOS:A1996TW58100006 | - |
dc.identifier.scopusauthorid | Chan, TM=7402687700 | en_US |
dc.identifier.scopusauthorid | Cheng, IKP=7102537483 | en_US |
dc.identifier.issnl | 0090-1229 | - |